Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.76 USD
+0.01 (0.57%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.75 -0.01 (-0.57%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 261 - 273 ( 273 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
June And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals-May and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Reported no surprises in their Q4/FY 2012 financials
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
KYNAMRO Approval Reduces Risk, In Our View; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage at OUTPERFORM and $10 Price Target - - Standing on the Shoulders of Giants - Advances on Many Fronts
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage at OUTPERFORM and $10 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G